Article

A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK.

Durrie Vision, Overland Park, KS 66211, USA.
Journal of Ocular Pharmacology and Therapeutics (Impact Factor: 1.42). 07/2005; 21(3):236-41. DOI: 10.1089/jop.2005.21.236
Source: PubMed

ABSTRACT The purpose of these two studies was to compare the safety and tolerability of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for use with laser-assisted in situ keratomileusis (LASIK) and laser-assisted subepithelial keratomileusis (LASEK) patients. Treatment with the two antibiotic regimens was randomly assigned to fellow eyes of each patient. The LASIK study showed no difference between the two therapies in terms of visual acuity, pupil size, SPK, edema, haze, day- and nighttime glare, halos, clarity of day or night vision, and dry eye symptoms up to 1 week after surgery. Patients reported no preference between the two antibiotics on the basis of ease of use, irritation, redness, itching, gritty, sandy or scratchy feeling, speed of recovery, overall vision, or overall comfort up to 7 days after LASIK surgery. Corneal healing after LASEK surgery was equivalent for the antibiotic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution. When comparing safety and tolerability, these findings suggest an equivalent role for these fluoroquinolone antibiotics in surgical prophylaxis.

0 Followers
 · 
72 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The aim of the study was to evaluate the safety of besifloxacin ophthalmic suspension 0.6% as antibacterial prophylaxis in the surgical setting. Methods: Two prospective safety surveillance studies were conducted—one in the cataract surgery setting and the other in the laser-assisted in situ keratomileusis (LASIK) surgery setting. Cases from patients aged 18 years and above were eligible for inclusion. In both surveillance studies, data were collected from consecutive cases of routine primary cataract surgery and LASIK surgery, respectively, in which besifloxacin ophthalmic suspension 0.6% or moxifloxacin ophthalmic solution 0.5% was used as the topical perioperative prophylactic antibacterial medication as part of the clinician's routine standard of care. The primary safety endpoint was the incidence of treatment-emergent adverse events (TEAEs). Results: The cataract surgery surveillance study included 485 cases/eyes (besifloxacin, n = 333; moxifloxacin, n = 152), whereas the LASIK surveillance study included 456 cases/eyes (besifloxacin, n = 344; moxifloxacin, n = 112). In the cataract study, only 1 TEAE was reported in a besifloxacin case (mild hypersensitivity/allergic reaction considered possibly related to besifloxacin). No TEAEs were reported in the LASIK study. In both studies, surgical outcomes were similar with both treatments. The frequency of preoperative and/or postoperative dosing was generally lower for besifloxacin than that for moxifloxacin. Conclusions: In prospective safety surveillance studies of patients undergoing cataract extraction or LASIK, TEAEs associated with prophylactic use of besifloxacin ophthalmic suspension 0.6% were rare, and surgical outcomes with besifloxacin were similar to those with moxifloxacin ophthalmic solution 0.5%.
    Cornea 03/2014; 33(5). DOI:10.1097/ICO.0000000000000098 · 2.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: This study was designed to evaluate the effects of topical moxifloxacin 0.5% ophthalmic solution (Vigamox) and gatifloxacin 0.3% ophthalmic solution (Zymar) on corneal wound healing for patients undergoing bilateral photorefractive keratectomy (PRK). Methods: Forty-three patients with low-to-moderate myopia (-1.00 to -7.00 D), ranging from 21 to 71 years of age, were randomized into 2 groups: moxifloxacin (n = 21) and gatifloxacin (n = 22). After bilateral PRK, antibiotics were administered in both eyes (fellow-eye design) immediately and then every 6 hours until complete wound healing had occurred. Slit-lamp fluorescein pictures were taken of each eye immediately after surgery and on postoperative days until complete wound healing had taken place. NIH software (Image J) was used to measure surface area of the defect. Results: Analysis showed no difference in the time of wound closure (P = 0.79). The mean healing rate for moxifloxacin was 0.8 mm2/h ± 0.2 (mean ± standard deviation), and 0.8 mm2/h ± 0.2 for gatifloxacin. There were no differences in the healing rates (P = 0.61), haze (P > 0.09), or in the postoperative uncorrected visual acuity (P > 0.66) at 1 month. Conclusion: Moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution produced similar results with respect to haze, visual acuity, and rate of corneal wound healing when administered to PRK patients.
    Cornea 09/2006; 25(9):S8-S11. DOI:10.1097/01.ico.0000176607.17871.6e · 2.36 Impact Factor
  • Source
    American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 02/2013; 70(3):195-283. DOI:10.2146/ajhp120568 · 2.21 Impact Factor